EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 09.01.2023 / 07:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 9, 2023 Morp.
MorphoSys Reports Preliminary 2022 Monjuvi U S Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability 05.01.2023 / 11:38 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release Planegg/Munich, G.
Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial